Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 5 min read

Which peptides are studied in relation to visceral fat?

A research-supply overview of peptides and related compounds investigated for visceral fat, including mazdutide, tesamorelin, and GLP-1 receptor agonists, with study designs and populations.

peptides-pro Editorial

Which peptides are studied in relation to visceral fat?

Peptides and peptide-related compounds studied in relation to visceral fat include mazdutide (a dual GLP-1/glucagon receptor agonist), tesamorelin (a growth hormone-releasing hormone analogue), and GLP-1 receptor agonists. These agents are investigated in clinical trials for their effects on visceral fat accumulation and related metabolic parameters. The evidence base includes randomized controlled trials and observational studies in populations with overweight, obesity, type 2 diabetes, and HIV-associated visceral adiposity.

The work centres on the GLP-1 receptor and related incretin pathways, as well as growth hormone-releasing hormone signalling, which influence adipose tissue distribution and metabolic function.

Research Studies

Mazdutide and fatty pancreas in overweight or obesity

A randomized, double-blind, placebo-controlled trial is evaluating mazdutide for improving fatty pancreas in patients with overweight or obesity. The study plans to enroll 194 participants, randomized 1:1 to mazdutide plus standardized lifestyle intervention or placebo plus standardized lifestyle intervention, for 48 weeks. The primary endpoint is change from baseline in pancreatic proton density fat fraction (PDFF) measured by MRI at week 48 [1].

Mazdutide and nonalcoholic fatty liver disease in type 2 diabetes

A multicenter, prospective, randomized controlled investigator-initiated trial is assessing the efficacy and safety of switching to mazdutide in Chinese patients with type 2 diabetes mellitus and moderate-to-severe nonalcoholic fatty liver disease who have achieved glycemic control. The study notes that Chinese patients with T2DM are susceptible to visceral fat accumulation, which increases cardiometabolic risk [2].

Tesamorelin and excess visceral abdominal fat in people living with HIV

Two clinical cases highlight distinct therapeutic pathways with tesamorelin and GLP-1 receptor agonists for excess visceral abdominal fat in people living with HIV-1. This pattern of fat accumulation occurs even in individuals with normal or mildly elevated BMI and is associated with metabolic dysfunction and cardiovascular risk [11].

Urolithin A and weight loss with muscle preservation in obesity

A study is testing whether daily Urolithin A (500 mg) for 6 months helps adults with obesity lose weight while preserving functional muscle mass and improving markers of mitochondrial health, inflammation, and metabolism. All participants receive a structured lifestyle program; half receive Urolithin A and half a placebo [5].

Resistin and visceral fat reduction after sleeve gastrectomy

A study is investigating whether serum resistin levels can predict the reduction in visceral fat following sleeve gastrectomy in patients with morbid obesity. The study focuses on visceral fat, which is linked to inflammation and type 2 diabetes, and on resistin as a marker of insulin resistance [6].

Barley green and visceral fat area in high body fat percentage

A randomized trial is examining changes in visceral fat area and associated indicators in individuals with high body fat percentage receiving barley green supplementation with a calorie-restricted diet, and exploring mechanisms through gut microbiota analysis [7].

Sclerostin, irisin, and leptin in Chinese men with obesity

A cross-sectional study in Chinese men with obesity explored the interactions among sclerostin, irisin, and leptin, and their associations with body composition and bone metabolism. Body composition was measured using dual-emission X-ray absorptiometry, and subcutaneous fat, visceral fat, and fat content in the liver and pancreas were determined by magnetic resonance. Serum levels of sclerostin, irisin, and leptin were detected using ELISA [3].

Body composition and IVF outcomes

A prospective observational cohort study is evaluating whether body composition measured by bioelectrical impedance analysis, including body fat percentage and visceral fat, serves as a better predictor than BMI of outcomes of in vitro fertilization cycles. Participants undergo body composition assessment prior to treatment [4].

Ethnic differences in adipose tissue dysfunction and type 2 diabetes

A pilot study is investigating the relationship between type 2 diabetes and adipose tissue dysfunction across different ethnic groups. Adipose tissue dysfunction is characterised by abnormal fat distribution, including increased visceral, hepatic, and pancreatic fat, elevated inflammatory biomarkers, and impaired metabolic function [8].

Bitter hop nutraceutical and fat mass loss

A study reports that a bitter hop nutraceutical stimulated fat mass loss while preserving muscle mass in a cohort of individuals with overweight or obesity receiving diet and exercise advice [10].

Circulating adipokines and body composition in ovarian carcinoma

A study examined circulating adipokines, tissue receptor expression, and body composition in patients with epithelial ovarian carcinoma, integrating these factors with clinical relevance and disease stage [9].

Hematopoietic stem cell transplantation-associated partial lipodystrophy

A report describes hematopoietic stem cell transplantation-associated partial lipodystrophy, a metabolic complication that develops in the remote period among childhood cancer survivors treated with HSCT with total body irradiation [12].

If you are reading this for personal health reasons

The compounds mentioned here are sold for laboratory research use only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp